Reviewed listing: NASDAQ:RIGL · Analysis dated Oct 13, 2026
How does the company make money?
Rigel develops and sells drugs for blood disorders and certain cancers. Since August 2026, a fourth drug for a particular form of advanced breast cancer has expanded its offering.
What supports the business?
Rigel is profitable and generates cash from ongoing operations. Drug sales rose by around 14 percent in the second quarter, even though sales of a cancer drug declined.
What could improve?
The breast cancer drug VEPPANU, offered since August, could generate additional revenue. The key is whether more profit actually remains after payments to the previous rights holders and additional costs.
How is the stock price assessed?
This assessment refers to the analysis and its quoted price shown here. It is not a live quote or a personal recommendation to buy.
48.81 USD are conditionally reasonable if sales success continues and launch costs remain manageable, but they are not a proven bargain. The exceptionally high annual profit 2025 makes the stock look cheaper than the business’s sustainably achievable performance justifies.
What is the main risk?
Rigel has already paid 70 million USD for the rights to the new breast cancer drug; additional payments and development costs may follow. If sales are weak, these burdens could significantly reduce earnings and available cash.
What is the overall assessment?
Rigel has a profitable drug business and a concrete opportunity to expand in the breast cancer market. At 48.81 USD, the common stock is conditionally defensible if costs remain manageable; however, increased operating expenses and extensive licensing obligations currently prevent a convincing opportunity assessment. Status: watch.
Continue exploring this stock in your account
A free Marqora account gives you the detailed analysis with further evidence and lets you compare and save stocks. Your selected stock is kept when you sign in or register.
Open the full analysis in a free account →
Already have an account? Sign inSources used in the analysis
- Original source 1 · api-v4.fcsapi.com
- Original source 2 · data.sec.gov
- Original source 3 · data.sec.gov
- Original source 4 · www.rigel.com · Mar 03, 2026
- Original source 5 · www.rigel.com · Aug 04, 2026
- Original source 6 · www.rigel.com · Aug 04, 2026
- Original source 7 · www.sec.gov · May 12, 2026
- Original source 8 · www.rigel.com · May 12, 2026
- Original source 9 · www.rigel.com · Jun 16, 2026
- Original source 10 · www.rigel.com · Aug 13, 2026
- Original source 11 · www.sec.gov